ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC grew its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 4.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 60,294 shares of the company’s stock after acquiring an additional 2,670 shares during the quarter. Wealth Enhancement Advisory Services LLC owned about 0.06% of ARS Pharmaceuticals worth $636,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Alliancebernstein L.P. increased its stake in ARS Pharmaceuticals by 5,168.4% during the fourth quarter. Alliancebernstein L.P. now owns 3,880,734 shares of the company’s stock worth $40,942,000 after acquiring an additional 3,807,074 shares during the last quarter. Vanguard Group Inc. increased its stake in ARS Pharmaceuticals by 3.5% during the fourth quarter. Vanguard Group Inc. now owns 3,464,952 shares of the company’s stock worth $36,555,000 after acquiring an additional 115,656 shares during the last quarter. Alyeska Investment Group L.P. increased its stake in ARS Pharmaceuticals by 903.0% during the fourth quarter. Alyeska Investment Group L.P. now owns 1,253,724 shares of the company’s stock worth $13,227,000 after acquiring an additional 1,128,724 shares during the last quarter. Geode Capital Management LLC increased its stake in ARS Pharmaceuticals by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 1,238,156 shares of the company’s stock worth $13,066,000 after acquiring an additional 3,351 shares during the last quarter. Finally, Woodline Partners LP boosted its position in shares of ARS Pharmaceuticals by 13.5% in the fourth quarter. Woodline Partners LP now owns 1,119,283 shares of the company’s stock worth $11,808,000 after buying an additional 133,276 shares during the period. 68.16% of the stock is currently owned by institutional investors and hedge funds.

ARS Pharmaceuticals Stock Performance

Shares of SPRY opened at $14.69 on Wednesday. The company has a market capitalization of $1.44 billion, a P/E ratio of -28.80 and a beta of 0.84. ARS Pharmaceuticals, Inc. has a one year low of $7.55 and a one year high of $18.51. The stock has a 50-day moving average price of $14.02 and a 200 day moving average price of $12.83.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, meeting analysts’ consensus estimates of ($0.35). The business had revenue of $7.97 million during the quarter, compared to analysts’ expectations of $7.48 million. As a group, equities research analysts forecast that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

Insider Activity at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, insider Eric Karas sold 10,000 shares of the stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. Following the transaction, the insider now owns 7,696 shares of the company’s stock, valued at $107,744. This trade represents a 56.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Brent L. Saunders sold 120,000 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $14.25, for a total value of $1,710,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 332,971 shares of company stock valued at $4,621,888. Insiders own 33.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Scotiabank assumed coverage on ARS Pharmaceuticals in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $30.00 target price for the company. William Blair reiterated an “outperform” rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Finally, Wall Street Zen lowered ARS Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $31.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.